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Effects of rHuEPO on Q-EEG and event-related potentials in chronic
renal failure. Quantitative electroencephalography is a powerful tool to
evaluate brain function, and preliminary data have shown its usefulness
in the evaluation of patients with chronic renal failure (CRF). In this
study, baseline values of different quantitative EEG variables, as well
as data from the P300 component of the visual event-related potential,
in 43 patients with chronic renal failure, were compared with those of a
group of healthy subjects and with the results obtained after 3, 6, 9 and
12 months of treatment of these patients with rHuEPO. Baseline total
power was much lower in patients with CRF than in healthy subjects,
and the distribution of power among the frequency bands was also
abnormal. rHuEPO promptly normalized total power and progressively
improved power distribution, although full normality was not achieved.
Mean dominant frequencies in brain areas were abnormal in patients
with CRF, and progressive improvement was seen along the study. The
latency of P300, which was increased before treatment, decreased in all
subjects, but normal values were not reached. The same applies to the
hypomanic and psychopathic scores of psychological tests. Altogether,
brain dysfunction of CRF seems to substantially improve by treatment
of the anemia with rHuEPO.
Anemia is a common complication of chronic renal failure
(CRF) and can be detected in over 90% of patients with this
condition [1]. Although there are many contributing factors to
this complication, the most important cause is a decrease in
erythropoietin production by the failing kidney [1—4]. On the
other hand, a uremic syndrome, mainly manifested as a neuro-
logical and neurobehavioral dysfunction, can be quantified by
neuropsychological and electrophysiological studies [5—9].
Chronic hemodialysis corrects the uremia of CRF, but careful
measurements show that it only affords a partial reversibility of
the neurobehavioral dysfunction [9—12]. This suggests that
uremic toxins are probably not the sole cause of the altered
brain function, and it has been suggested that anemia could play
a substantial role. Availability of recombinant human erythro-
poietin (rHuEPO) has offered a tool to test this hypothesis, and
reports have already been published showing an improvement
in cognitive function, assessed by psychological tests and the
P300 component of the event-related potential, in CRF patients
treated with erythropoietin [13—15].
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Central nervous system alterations in CRF are not necessar-
ily limited to cognitive function. Quantitative EEG is a powerful
tool to evaluate brain dysfunction [16—18] and has elicited
differences between normal subjects and patients with CRF that
can partially be corrected by peritoneal dialysis or hemodialysis
[20—22]. In this context, it seemed of interest to evaluate the
effects of treatment with rHuEPO on brain function in patients
with CRF, using quantitative EEG and brain mapping, together
with other electrophysiological and neuropsychological mea-
surements.
Methods
Subjects
A group of 43 patients (17 males, 26 females; age range: 22 to
74, median 66 years) with CRF currently on center hemodialy-
sis at least for the last six months has been studied. The original
diagnoses were: interstitial nephropathy (N = 7), nephroscle-
rosis (N = 7), diabetic nephropathy (N = 8), chronic glomeru-
lonephntis (N = 5), chronic pyelonephritis (N = 5), focal
glomerulosclerosis (N = 2), and toxic nephropathy (N = 2).
CRF was not typified in seven cases.
All patients had been under hemodialysis treatment thrice
weekly during the six month period prior to initiation of the
study. All them had been previously polytransfused. Mean
duration of the hemodialysis treatment since its onset was 52
months. Mean basal hemoglobin values were 70 5 g/liter.
None of them had primary central nervous system disease or
uncontrolled arterial hypertension. Throughout the study, the
hemodialysis program was kept unchanged, that is, all patients
were submitted to dialysis thrice weekly. Hemodialysis was
performed with a hollow-fiber cuprophane dialyzer of 1 to 1.3
m2. Blood pump speed was 200 to 300 mllmin, and the flow of
the dialysis fluid was kept constant at 500 ml/min. Length of the
dialysis session was three to four hours. Blood urea nitrogen
was 183.0 22.0 mg/100 ml at the beginning of the study and
168.0 27.0 mg/lOO ml 12 months thereafter. Corresponding
values of serum creatinine were 12.3 1.9 and 12.1 1.3
mg/100 ml.
rHuEPO was also administered thrice weekly, upon termina-
tion of each dialysis session, with an initial dose of 40 U/kg until
a hemoglobin concentration of 100 g/liter was reached. This
happened shortly before completion of the first trimester of
treatment in all cases. Mean inantainance dose was 37.9 U/kg
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thrice weekly. No blood transfusions were administered to any
of the patients during the study, and none of them suffered any
intercurrent illness that would affect the central nervous sys-
tem. A day in between hemodialysis treatment was selected to
perform all the explorations.
A group of eight healthy volunteers (age range: 31 to 70,
median 65 years) was used as a baseline control.
Quantitative EEG and brain mapping
Patients were evaluated before rHuEPO treatment (TO) and
after 3 (T3), 6 (T6), 9 (T9) and 12 (T12) months of continuous
treatment.
An electrodes cap was used for EEG recording, with the
10—20 International System placement. Linked-ear electrodes
were used as reference. An 18 channel Nicolet EEG 1A97 and
a Nicolet Brainlab were used for the recording. The pass band
of the amplifier was set between 0.5 and 30 Hz. Twenty
artifact-free epochs of four second duration were recorded and
analyzed. That means a total of 80 seconds of cerebral electrical
activity free from artifacts. A computerized artifact rejection
mechanism, together with visual control, was used in the
selection of the epochs. Eye blinks, muscle activity, vascular
pulses and electrode artifacts were detected and rejected, as
well as periods of drowsiness. Screening was done by two
authors thoroughly experienced in routine electroencephalog-
raphy and evoked potentials.
The EEG is a complex waveform whose amplitude and
frequency varies with time, but quantitative data can be ex-
tracted from it. The "power" of the signal, measured in V2 is
the square of the signal effective value [23], and a typical
approach is to obtain the Power Spectral Density (PSD) of the
EEG signal. The PSD gives the distribution of the EEG total
power among the frequencies. In this study, total EEG power
and power in each of the classical frequency bands differenti-
ated in EEG recordings, that is, delta (0.5 to 3.75 Hz), theta (4
to 7.75 Hz), alpha (8 to 11.75 Hz), beta-i (12 to 15.75 Hz),
beta-2 (16 to 19.75 Hz) and beta-3 (20 to 24 Hz) were calculated.
Mean dominant frequency (MDF), extracted from the PSD
function and measured in Hz was also calculated. Power in the
different bands and MDF were calculated for five cerebral
areas: frontal, temporal, central, parietal and occipital.
Brain mapping [24] is a medical imaging technique based on
computerized EEG that shows, in the form of a two-dimen-
sional color distribution map, the brain activity in the different
scalp areas. Power in the different EEG frequency bands is
typically represented.
EEG recordings are customarily obtained in resting subjects
with their eyes closed. Recordings with eyes open are markedly
different, and with the advent of computerized EEG this
difference is routinely used as an indication of central nervous
system reactivity. In this study, brain maps were obtained in all
cases under two different conditions: (a) awake, eyes closed.
During the recording the subjects were resting with closed eyes,
and (b) awake, eyes open. During the recording the subjects
were in a resting position, but they were asked to look at a
central point placed at a distance of three meters.
Table 1. Total EEG power in control subjects and in patients with
CRF before (TO) and after 3 (T3), 6 (T6) 9 (T9) and 12 (T12) months
of treatment with rHuEPO
N
Recording p.V2
Eyes closed Eyes open
Control (8) 1620.0 350.0 1117.9 269.0
CRF TO (30) 725.5 490.Oa 551.3 3397a
T3 (30) 3486.5 128O.0c 2144.8 79g•0b
T6 (25) 2122.1 l275,9I,e 1495.2 95O.O
T9 (21) 2253.8 10450b.C 1252.7 894.6)c
T12 (21) 1145.0 4993C 751.9 282.Oc
Figures between parenthesis indicate the number of patients com-
pleting the test at each particular period. Values are mean SD.
a p < 0.05 for the difference when compared with the control group
bP < 0.05 for the difference when compared with baseline values
(TO)
Not statistically different from values in the control group
Event-related potentials
Event-related potentials (ERP) were also recorded before
initiation of rHuEPO treatment and 12 months thereafter in 10
of the 43 patients.
A visual "oddball" detection task was used for the collection
of ERP. A black and white chessboard pattern stimulus was
used as frequent stimulus (non-target stimulus), randomly re-
placed occasionally (18% of stimuli) by a red and black chess-
board pattern stimulus (target stimulus). Subjects were in-
structed to ignore the first ones and keep an internal addition of
the target stimuli. Trial was finished after a total of 22 artifact-
free responses to target stimuli. Frequency band width was set
between 0.5 and 30 Hz.
The P300 wave of the ERP was identified as the large positive
wave appearing 280 msec or later after the onset of the stimulus,
that was present in responses to target stimuli and absent, or
greatly decreased, in responses to non-target stimuli. The Pz
channel was chosen to measure the latency and amplitude of the
different waves of the ERP.
Neuropsychological assessment
The MINIMULT and WAIS test (digits, dices, similarities
and unfinished figures) were performed in 18 of the 43 patients,
before and after 12 months of rHuEPO treatment.
Statistical analysis
Student's t-tests for nonpaired data and for paired data were
used in the statistical analysis of the EEG and P300 data.
Nonparametric Wilcoxon's test for paired data was used in the
statistical analysis of neuropsychological data [25].
Results
Brain mapping
Power values and brain maps for the control group and in
patients with CRF, before and after different treatment periods
with rHuEPO, are presented in Table 1 and Figure 1. As shown
there, baseline total power in patients with CRF was much
lower than in normal subjects (1620.0 350.0 vs. 725.5 490.0
V2, P < 0.05, in recordings with eyes closed, and 1117.9
269.0 vs. 551.3 339.7 P < 0.05, in recordings with the
eyes open). Another differential feature between the two groups
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Fig. 1. Pooled brain EEG maps for the different frequency bands of control sujects (CG, top) and of patients with CRF, before (TO) and after 3
(T3), 6 (T6), 9 (T9) and 12 (T12) months of treatment with rHuEPO. Maps obtained from recordings with the eyes closed. Color entries are in
increasing order from ito 70 V2. Reproduction of this figure in color was made possible by a grant from Boehringer Mannhein S.A., Barcelona,
Spain.
was the distribution of power among the frequency bands. As
expected, eyes closed recordings in normal subjects revealed a
dominancy of alpha power, with peak values in occipital areas,
that was not seen in patients. Also, the increase in delta
activity, elicited by recording with the eyes open, was much
more marked in patients than in normal subjects.
Continuous treatment with rHuEPO promptly normalized
total power in the brain. Values after three months were much
greater than baseline and not statistically different from those in
the control group, in both recording conditions, and the same
was observed in later evaluations. Progressive changes toward
normality were detected in the maps recording power distribu-
tion in the brain after 3, 6, 9 and 12 months of treatment, but a
completely normal distribution was not achieved. Analysis of
data from the eight patients that were tested at all five time
points yielded similar results, that is, statistically different
values from baseline recordings were already observed after
three months of treatment and this change persisted in later
evaluations. Even in this limited and more homogeneous group,
power tended to be greater at T3, with a progressive decrease at
T6, T9 and T12. This trend was similar in different age or length
of disease groups analyzed.
Figure 2 illustrates the statistical significance of the changes
in eyes closed/eyes open reactivity along the study in patients
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Fig. 2. Eyes closed/eyes open reactivity:
Distribution maps of P values. Differences
between brain maps obtained with eyes
open and maps with eyes closed were
evaluated in patients with CRF before (TO)
and after 3 (T3), 6 (T6), 9 (T9) and 12 (T12)
months of rHuEPO treatment. White color
identifies areas in which no statistically
significant differences were observed. Grey
areas indicate P values below 0.05. Black
areas indicate P values below 0.01.
treated with rHuEPO. Again, progression toward normality is
evident.
Mean dominant frequency (MDF) in different brain areas in
sequential recordings along the study is presented in Figure 3.
With eyes closed, the typical preponderance of higher frequen-
cies in the occipital areas was elicited in normal volunteers,
whereas a rather uniform distribution of the different frequen-
cies among the different areas was seen in patients with CRF.
Again, treatment with rHuEPO promptly normalized the fre-
quency distribution, and the effect was maintained throughout
the study.
P300
Patients with CRF exhibited a P300 amplitude similar to that
observed in healthy subjects (10.1 4.5 vs. 11.3 1.9 MV), but
an increased latency of this wave (376.1 15.5 vs. 441.1 26.5
msec, P < 0.05) was detected.
No consistent changes were noted in the P300 wave ampli-
tude before and after 12 months of rHuEPO treatment, whereas
a decrease of P300 latency was observed in all patients. The
mean P300 latency of 441.1 26.5 msec was reduced to 418.3
24.7 msec after 12 months (Table 2).
Psychological tests
Tests performed on 18 patients before and after 12 months of
continuous treatment with rHuEPO revealed statistically signif-
icant changes in psychopathic and hypomanic scores of
MINIMULT. In the clinical psychopathic scores, the initial
values of 53.2 3.4 decreased to 48.4 6.5 (P < 0.05),whereas
the baseline hypomanic score of 46 6.7 decreased to 41 5.5
(P < 0.05). WAIS scores were not modified by rHuEPO
treatment.
Discussion
Our results clearly show that quantitative EEG and brain
mapping are powerful tools to evaluate the central nervous
system dysfunction of chronic renal failure. Power spectral
density relates amplitude and frequency of the electrical waves
originating from cerebral activity. This integrated variable was
clearly depressed in our patients with CRF when compared
with a control group of healthy volunteers of the same age
range. Furthermore, when power for the different frequency
bands was evaluated in the different brain areas currently
considered in EEG evaluations (frontal, central, temporal and
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Table 2. P300 latency and amplitude in control subjects and in
patients with CRF, before (TO) and after 12 (112) months of
treatment with rHuEPO
N
P300 latency
ms
P300 amplitude
1sV
Control (8) 376.1 15.5 10.1 4.5
CRFTO (10) 441.1 26.5a 11.3 1.9
CRF T12 (6) 418.3 24.7a 11.5 2.5
Figures between parenthesis indicate the number of subjects com-
pleting the test at each period. Values are mean SD.
a P < 0.05 for the difference with the control group
occipital), patients with CRF exhibited an abnormal distribu-
tion. This was reflected by a loss of the characteristic domi-
nancy of the alpha activity in the occipital areas and by an
abnormal reactivity to the change in recording conditions
represented by keeping the eyes open.
Focus on the frequencies of brain electrical activity also
differentiated patients with CRF from healthy subjects. In the
control group, clear cut differences in the mean dominant
frequency were observed among different brain regions. Lower
frequencies were dominant in the frontal areas, while progres-
sively higher frequencies dominated in the central, temporal
and occipital areas. This pattern was completely lost in patients
with CRF, in which no substantial differences in MDF were
elicited among brain areas.
Treatment of the anemia in these patients by continuous
administration of rHuEPO for 12 months resulted in a prompt
improvement of the above-mentioned abnormalities. Three
months after initiation of treatment, when hemoglobin concen-
trations were equal or above 100 glliter in all cases, total power
was more than twice that of baseline recordings and had
reached a mean value not statistically different from that of the
control group. Normal power values were recorded from then
on.
Distribution of power for the different frequency bands also
Fig. 3. Mean dominant frequency (Hz) in
four dffferen( brain areas in control subjects
(CG, left) and of patients with CRF, before
(TO) and after 3 (T3), 6 (T6), 9 (T9) and 12
(T12) months of treatment with rHuEPO.
Symbols are: (s), frontal areas; (n), central
areas; (l) temporal areas, (), occipital
areas.
proved sensitive to treatment with rHuEPO, but in this case the
effects took longer to establish. After three months of treat-
ment, the brain maps were still quite abnormal, although alpha
activity was increased in occipital areas. Power distribution was
not much improved after six months of treatment, and even
after 12 months some abnormalities persisted in the brain maps.
Thus, although the distribution of alpha and beta activities
could be considered roughly normal, there was still an excess of
slow activities throughout the brain.
It is worth commenting on the slightly different results
yielded by evaluation of total power and of brain mapping.
Power quantification indicates that a therapeutic response to
rHuEPO is seen after three months of treatment, when values
are statistically different from baseline but not from those
obtained in normal subjects. After this point, however, numer-
ical values seem to decrease and the impression left is that there
is some kind of "escape" to treatment. On the other hand, brain
maps prove more sensitive. Maps at T3 are different from those
in healthy subjects and progressive changes are seen at later
points, normality being approached, but not fully achieved.
Interestingly, brain maps also offer a clue for the interpretation
of the apparent escape effect seen in total power analysis.
Inasmuch as EEG power reflects amplitude (square) versus
frequency of the electrical signal of the brain, an increase of
delta activity, as detected at T3 and T6, would result in greater
total power values than would be expected if lower frequencies
predominated.
The effects of erythropoietin treatment were also reflected in
the values of the mean dominant frequency in different brain
areas. The increase in alpha activity in the occipital areas after
three months of treatment led to a partial normalization of the
distribution of MDFs at that time, but distributions closely
resembling those observed in healthy subjects were not ob-
served until after 9 or, to a greater extent, 12 months of
rHuEPO treatment.
The marked improvement of brain function, as elicited by
quantitative EEG and brain mapping, after continuous rHuEPO
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treatment for one year, parallels the effects observed in another
electrophysiological measurement, namely the latency of P300
wave of the event-related potential. The abnormal latency of
this wave in patients with CRF when compared with a group of
healthy volunteers was clearly diminished after 12 months. This
change was observed in all subjects, which strongly suggests a
treatment effect, but mean values did not reach normality.
Similar considerations apply to the results of psychological
tests, which elicited an improvement, but not full normaliza-
tion, of the psychopathic and hypomanic scores.
Our baseline evaluation of patients with CRF by means of
quantitative EEG yields results which are in agreement with
those of other studies [19—21], and the same applies to the
studies using P300 as an indicator of brain dysfunction in these
patients [9, 13—15]. Previous studies of quantitative EEG in
CRF have only focused on the effects of peritoneal dialysis or
hemodialysis, but none has considered the possible effects of
improvement of the anemia. In the case of P300, several studies
have dealt with the effects of rHuEPO treatment for different
periods of time up to one year [13—15]. In a study of the effects
of a six month treatment, Grimm el al [131 also observed a
partial normalization of P300 latency, with moderate but not
statistically significant effects on P300 amplitude induced by
rHuEPO. It should be mentioned that the event-related poten-
tial in that study was elicited by means of acoustic stimuli,
whereas in our case the stimuli were visual. This is obviously an
important difference. Acoustic stimuli were also used in the
studies of Brown et al [14] and of Marsh et al [15], which
reported no effects of rHuEPO treatment on P300 latencies.
However, in both cases there are indications, acknowledged by
the authors, that the patients studied were less ill than those of
Grimm et al and, as judged by the published data, than ours.
The lack of full normalization of several electrophysiological
variables (power distribution, P300 latency) in spite of marked
improvement of the anemia after a 12 month treatment with
rHuEPO, when hematocnt levels were above 30 in all cases,
suggests that factors other than anemia also account for the
neurobehavioral dysfunction of patients with CRF. Whatever
the role of hormonal or other factors [22, 25—27] in uremic
encephalopathy, it seems evident that decreased oxygen deliv-
ery to the brain due to anemia is an important determinant of
the electrophysyiological abnormalities detected in patients
with chronic renal failure, and that treatment of the anemia with
rHuEPO results in a substantial reversal of these abnormalities,
as well as an improvement in the scores of psycopathic and
hypomaniac traits in psychological tests.
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